Zoledronate in Preventing Bone Loss in Postmenopausal Women Who Are Receiving Letrozole for Stage I, Stage II, or Stage IIIA Breast Cancer
PHASE3CompletedINTERVENTIONAL
Enrollment
558
Participants
Timeline
Start Date
January 31, 2005
Primary Completion Date
March 31, 2007
Study Completion Date
August 31, 2012
Conditions
Breast CancerOsteoporosis
Interventions
DRUG
letrozole
DRUG
zoledronic acid
All Listed Sponsors
collaborator
National Cancer Institute (NCI)
NIH
lead
Alliance for Clinical Trials in Oncology
OTHER
NCT00107263 - Zoledronate in Preventing Bone Loss in Postmenopausal Women Who Are Receiving Letrozole for Stage I, Stage II, or Stage IIIA Breast Cancer | Biotech Hunter | Biotech Hunter